Lacosamide

拉考沙胺

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameLacosamide
Drug Alias Name拉克酰胺HarkoserideLacosamidumLacosamidaErlosamide +[11
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel alpha subunit blockersGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptorSodium channel alpha subunit
Therapy Area/IndicationsBipolar DisorderOpioid-Related DisordersAlcoholism +[22
Global Approved IndicationsEpilepsies, PartialEpilepsy
Approved Indications in ChinaEpilepsy
Original Approved Country/TerritoryEU
Original Approved Date2008/08/29
Country/TerritoryCzechiaBelgiumBulgaria +[51
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesUcb
China Registration ClassN/A

Develop Information

Active IndicationsBipolar DisorderOpioid-Related DisordersChronic Pain +[12
Inactive IndicationsAlcoholismRenal InsufficiencyNeuralgia, Postherpetic +[10

Other Information

ATC CodeN03AX18